Literature DB >> 7231897

Amblyopia caused by unilateral atropinization.

G K von Noorden.   

Abstract

Unilateral atropinization is used in infants and children in the treatment of amblyopia (penalization). It is also used to prevent amblyopia in eyes with cataracts involving only the central portions of the lens. It is not generally realized, however, that unilateral atropinization during visual immaturity may actually cause amblyopia. Three reported cases demonstrate this point. Experiments in monkeys raised with unilateral cycloplegia demonstrated shrinkage of cells in the lateral geniculate nucleus and loss of cortical binocularity and of neurons responding to stimulation of the atropinized eye. The clinical data reported in this study, in conjunction with information gleaned from animal models, indicate that caution must be applied when considering prolonged unilateral atropinization of infants and young children.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7231897     DOI: 10.1016/s0161-6420(81)35063-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  6 in total

1.  Progression of myopia.

Authors:  R H Kennedy
Journal:  Trans Am Ophthalmol Soc       Date:  1995

2.  Photorefractive keratectomy for anisometropic amblyopia in children.

Authors:  Evelyn A Paysse
Journal:  Trans Am Ophthalmol Soc       Date:  2004

3.  Refractory reverse amblyopia with atropine penalization.

Authors:  Preeti Ajit Patil; S Meenakshi; T S Surendran
Journal:  Oman J Ophthalmol       Date:  2010-09

4.  Practical management of amblyopia.

Authors:  G K von Noorden
Journal:  Int Ophthalmol       Date:  1983-01       Impact factor: 2.031

5.  Pharmacological plus optical penalization treatment for amblyopia: results of a randomized trial.

Authors: 
Journal:  Arch Ophthalmol       Date:  2009-01

Review 6.  The role of drug treatment in children with strabismus and amblyopia.

Authors:  K I Chatzistefanou; M D Mills
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.930

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.